What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
The scientist’s investigation covers issues in Internal medicine, Surgery, Oncology, Endocrinology and Gastroenterology.
The concepts of his Internal medicine study are interwoven with issues in Diabetes mellitus and Pathology.
His studies examine the connections between Surgery and genetics, as well as such issues in Cancer, with regards to Loss of heterozygosity.
His study in the field of Induction chemotherapy is also linked to topics like In patient.
The Endocrinology study combines topics in areas such as Maternal hypothyroidism, Birth weight and Inflammatory bowel disease.
His research in Gastroenterology intersects with topics in Irinotecan, Neutropenia, Toxicity, Proctocolectomy and Genotype.
His most cited work include:
- Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. (828 citations)
- UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity (588 citations)
- Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. (532 citations)
What are the main themes of his work throughout his whole career to date?
Theodore Karrison focuses on Internal medicine, Oncology, Surgery, Gastroenterology and Cancer research.
His research combines Endocrinology and Internal medicine.
In Oncology, he works on issues like Cancer, which are connected to Toxicity.
He works on Surgery which deals in particular with Prospective cohort study.
His Gastroenterology study combines topics from a wide range of disciplines, such as Irinotecan and Neutropenia.
His Irinotecan research integrates issues from Tolerability, Genotype and Dosing.
He most often published in these fields:
- Internal medicine (48.46%)
- Oncology (29.69%)
- Surgery (14.01%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (48.46%)
- Oncology (29.69%)
- Gastroenterology (9.50%)
In recent papers he was focusing on the following fields of study:
Internal medicine, Oncology, Gastroenterology, Pembrolizumab and Randomized controlled trial are his primary areas of study.
Theodore Karrison applies his multidisciplinary studies on Internal medicine and In patient in his research.
The various areas that Theodore Karrison examines in his Oncology study include Androgen deprivation therapy, Prostate cancer, Ipilimumab, Immunotherapy and Radiation therapy.
The study incorporates disciplines such as Oxaliplatin, Anastomosis and Cohort in addition to Gastroenterology.
The concepts of his Pembrolizumab study are interwoven with issues in Previously treated and Mesothelioma.
He interconnects Tocilizumab, Low dose and Confidence interval in the investigation of issues within Randomized controlled trial.
Between 2017 and 2021, his most popular works were:
- Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. (219 citations)
- Short Term Androgen Deprivation Therapy Without or With Pelvic Lymph Node Treatment Added to Prostate Bed Only Salvage Radiotherapy: The NRG Oncology/RTOG 0534 SPPORT Trial (74 citations)
- Optima: A phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer (61 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
His primary scientific interests are in Internal medicine, Oncology, Pembrolizumab, Randomized controlled trial and Gastroenterology.
His research related to Interquartile range, Clinical endpoint, Lymph node, Androgen deprivation therapy and Salvage radiotherapy might be considered part of Internal medicine.
His research integrates issues of Cancer, Human Papillomavirus Positive, Immunotherapy, Disease and De-escalation in his study of Oncology.
His research in Pembrolizumab intersects with topics in Previously treated, Mesothelioma, Biopsy, Melanoma and Ipilimumab.
His Randomized controlled trial research is multidisciplinary, incorporating elements of Tocilizumab, Low dose, Phases of clinical research and Premature birth.
His study in Gastroenterology is interdisciplinary in nature, drawing from both Irinotecan, Oxaliplatin, Retrospective cohort study, Colon surgery and Cohort.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
